Human Genome Returning 13% With Bet On Glaxo Sweetener

Human Genome, which makes treatments for lupus and diabetes, has traded above Glaxo’s $13-a-share bid every day since it was rejected in April, according to data compiled by Bloomberg. After less than 1 percent of investors tendered their shares before Glaxo extended the offer last week, the stock closed at $13.29 yesterday, signaling traders who profit from acquisitions still expect the U.K. drugmaker to boost the price.

Leave a Reply

Reset password

Enter your email address and we will send you a link to change your password.

Get started with your account

to save your favourite homes and more

Sign up with email

Get started with your account

to save your favourite homes and more

By clicking the «SIGN UP» button you agree to the Terms of Use and Privacy Policy
Powered by Estatik
error: Content is protected !!